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SUMMARY
Chemogenetic technologies, including the mutated human Gq-coupled M3 muscarinic receptor 
(hM3Dq), have greatly facilitated our ability to directly link changes in cellular activity to altered 
physiology and behavior. Here, we extend the hM3Dq toolkit with recombinase-responsive mouse 
lines that permit hM3Dq expression in virtually any cell type. These alleles encode a fusion 
protein designed to increase effective expression levels by concentrating hM3Dq to the cell body 
and dendrites. To illustrate their broad utility, we targeted three different genetically defined cell 
populations: noradrenergic neurons of the compact, bilateral locus coeruleus and two dispersed 
populations, Camk2a+ neurons and GFAP+ glia. In all three populations, we observed 
reproducible expression and confirmed that activation of hM3Dq is sufficient to dose-dependently 
evoke phenotypic changes, without extreme phenotypes associated with hM3Dq overexpression. 
These alleles offer unprecedented ability to noninvasively control activity of diverse cell types to 
uncover their function and dysfunction at any developmental stage.
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 INTRODUCTION
Since their initial description less than ten years ago (Armbruster et al., 2007), the 
engineered G protein-coupled receptors known as DREADDs (Designer Receptors 
Exclusively Activated by Designer Drugs) have proven invaluable for linking cellular 
activity to changes in physiology and behavior. Among the most frequently used DREADDs 
is hM3Dq, a mutated Gq-coupled human M3 muscarinic receptor that is activated 
exclusively by the designer drug clozapine N-oxide (CNO), but not its native ligand 
acetylcholine. By coupling to endogenous signal transduction pathways, hM3Dq has 
provided insight into the unique functions of cells as diverse as neurons, glia, pancreatic β-
cells, and hepatocytes (as reviewed in Urban and Roth, 2015). In neurons, activation of 
hM3Dq by CNO leads to calcium influx and increased cell firing, thereby promoting 
neuronal excitability (Alexander et al., 2009). Thus, hM3Dq has been of particular value for 
identifying the functions encoded by specific neurons in the freely behaving animal.
Previous methods for delivery of hM3Dq to cells in vivo have included viral vectors, 
transgenes, and targeted knock-in mouse lines (Urban and Roth, 2015; Zhu and Roth, 2014). 
Each of these strategies drive hM3Dq expression at levels sufficient for behavioral or 
physiological analyses, but each has limitations. The most commonly used method for 
delivery of hM3Dq is injection of viral vectors. Although these constructs often generate 
very high levels of hM3Dq expression, overexpression may result in extreme phenotypes of 
questionable physiological relevance. Furthermore, the requirement for direct injection 
limits the use of viruses prenatally and in juvenile/adolescent animals. Multiple injections 
are required to target dispersed or bilateral cell populations, increasing the possibility of 
experimentally significant trauma and variable expression among experimental subjects. 
Some of the experimental limitations of viral vectors can be overcome by the use of 
transgenes. Given an appropriate promoter, transgene expression can be achieved non-
invasively in anatomically dispersed populations at any stage of development. However, 
each targeted cell population requires generation of a unique transgenic line, and multi-copy 
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transgene arrays can result in unpredictable expression levels. In contrast, single-copy 
knock-in alleles, particularly recombinase-responsive constructs, offer consistent, 
reproducible expression and the broadest range of possible cellular targets by partnership 
with existing cell type-specific recombinase driver lines. However, expression levels of 
single-copy alleles are likely to be lower than those achieved with viruses or transgenes.
To overcome these experimental challenges, we generated two recombinase responsive 
knock-in alleles that complement existing hM3Dq constructs by permitting non-invasive 
targeting of hM3Dq to the cell body (soma) and dendrites of genetically defined cells. This 
somatodendritic localization is designed to concentrate hM3Dq, thus increasing its effective 
expression level. Our Cre-responsive allele permits expression of hM3Dq in genetically 
defined cell populations by taking advantage of the many available cell type-specific Cre 
driver alleles. Because control by a single recombinase defines relatively broad classes of 
cells, we have also generated a Flp/Cre-responsive allele which restricts hM3Dq to the 
narrow intersection of two broader recombinase expression domains. hM3Dq is expressed 
only in those cells that have expressed Flp and Cre drivers, each controlled by the promoters 
of different genes, thus allowing functional manipulation of cell populations that cannot be 
defined by a single gene.
In this manuscript, we confirm that both alleles permit expression of an hM3Dq-mCherry 
fusion protein detectable at single-cell resolution in live and fixed tissue from embryos or 
adult mice. Furthermore, we demonstrate the broad utility of the alleles in three different cell 
populations: noradrenergic neurons of the small, bilateral locus coeruleus and two dispersed 
cell populations, Camk2a+ neurons and GFAP+ glia. In a proof-of-principle experiment 
using our Flp/Cre-responsive allele, we demonstrate that CNO increases neuronal firing of 
hM3Dq-expressing locus coeruleus neurons in vitro. We then demonstrate the in vivo 
effectiveness of the Flp/Cre-responsive allele by inducing anxiety-like behavior observed 
following activation of locus coeruleus neurons (McCall et al., 2015). Next, we evaluate the 
in vivo utility of our Cre-responsive allele by evoking physiological signatures ascribed to 
activation of Camk2a+ neurons (Alexander et al., 2009) and GFAP+ glia (Agulhon et al., 
2013), specifically hippocampal gamma oscillations and profound depression of body 
temperature, respectively. Collectively, these findings demonstrate that our hM3Dq alleles 
permit activation of genetically defined cell populations in a reproducible, dose-dependent 
manner and are valuable additions to the DREADD toolkit.
 RESULTS
 Generation of Flp/Cre and Cre recombinase-responsive alleles for somatodendritic 
targeting of hM3Dq
To ensure expression of our Flp/Cre-responsive (RC::FL-hM3Dq) and Cre-responsive 
(RC::L-hM3Dq) alleles in a wide range of cell types and developmental stages, we used a 
synthetic CAG promoter (Niwa et al., 1991) and targeted the Gt(ROSA)26Sor locus 
(Friedrich and Soriano, 1991) in mouse embryonic stem cells (Figure 1A). In RC::FL-
hM3Dq (Rosa-CAG-FRT-lox-hM3Dq), a FRT-flanked transcriptional stop cassette (Sauer, 
1993) following the CAG promoter prevents transcription of all downstream sequence until 
it is excised by Flp recombinase. The allele also encodes eGFP and an hM3Dq-mCherry 
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fusion protein with a c-terminal epitope (2ACT88) that mediates localization of the hM3Dq 
receptor to the cell body (soma) and dendrites (Xia et al., 2003). To prevent expression in the 
absence of Cre recombination, the hM3Dq-mCherry cDNA is inverted in a Cre-dependent 
FLEx switch consisting of two pairs of antiparallel lox sites (Atasoy et al., 2008; Schnutgen 
et al., 2003). Cre activity results in inversion of hM3Dq-mCherry to the proper orientation 
for transcription. RC::FL-hM3Dq will express eGFP following Flp-mediated recombination 
and hM3Dq-mCherry after recombination by both Flp and Cre. RC::L-hM3Dq (Rosa-CAG-
lox-hM3Dq) lacks the FRT-flanked stop cassette but is otherwise identical to RC::FL-
hM3Dq. Therefore, RC::L-hM3Dq will express eGFP in the absence of recombinase activity 
and hM3Dq-mCherry after Cre-mediated recombination. Because the recombination events 
are irreversible, cells will express hM3Dq-mCherry continuously, even if recombinase 
expression is transient. Thus, RC::L-hM3Dq expresses hM3Dq-mCherry in broad 
populations of cells defined by a single promoter that drives Cre expression. RC::FL-hM3Dq 
allows restriction of hM3Dq-mCherry to more specific subpopulations defined by shared 
expression of Flp and Cre driven by different promoters.
To confirm that the CAG promoter is broadly active and that hM3Dq-mCherry expression is 
efficiently controlled by recombinase activity, we examined eGFP and mCherry 
fluorescence in RC::FL-hM3Dq and RC::L-hM3Dq embryos and adults. In the absence of 
recombinase activity, we observed neither eGFP nor mCherry expression in RC::FL-hM3Dq 
embryos (Figure 1B) and adult brain (Figure S1), due to the intact stop cassette and FLEx 
switch. Following germline excision of the FRT-flanked stop cassette (RC::L-hM3Dq), we 
observed ubiquitous expression of eGFP but no mCherry. Subsequent germline 
recombination of the FLEx switch in RC::L-hM3Dq mice resulted in ubiquitous mCherry 
expression in both embryos and adult brain (Figure 1B and Figure S1). Thus, the CAG 
promoter is active throughout development, and both the FRT-flanked stop cassette and Cre-
dependent FLEx switch are capable of controlling expression of the proteins encoded by our 
two alleles.
To demonstrate the widest possible expression of hM3Dq-mCherry, we crossed RC::FL-
hM3Dq to the ubiquitously expressed ACTB-Flpe (Rodriguez et al., 2000) and ACTB-cre 
(Lewandoski et al., 1997) recombinase drivers. We observed hM3Dq-mCherry expression in 
a wide variety of cell types throughout the brain (Figure 2). Next, we used cell type-specific 
drivers to test whether our alleles can direct somatodendritic localization of hM3Dq-
mCherry in restricted cell populations. We used RC::L-hM3Dq in combination with 
Camk2a-cre (Tsien et al., 1996) or GFAP-creERT2 (Casper et al., 2007) transgenes for 
expression of hM3Dq-mCherry in neurons or glia, respectively. As expected, mCherry 
fluorescence was restricted to the soma and dendrites of neurons in the well-documented 
expression domain of the Camk2a-cre-transgene (Sonner et al., 2005), including cortical and 
hippocampal neurons (Figure 3A-B, Figure S2). Using the glial-specific GFAP-creERT2 
transgene, we observed restricted mCherry fluorescence in the soma and processes of glia 
defined by Gfap expression (Figure 3C, Figure S3). To demonstrate intersectional Flp/Cre 
control of RC::FL-hM3Dq, we targeted a population of noradrenergic neurons defined by a 
shared history of both En1cre and DbhFlpo expression (Robertson et al., 2013). This 
combination of recombinase drivers restricts hM3Dq-mCherry expression to a subpopulation 
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of noradrenergic neurons (hereafter designated LC complex), which encompasses 99.8% of 
the compact locus coeruleus (LC) and a portion of the dorsal subcoeruleus and A7 
noradrenergic nuclei (Robertson et al., 2013; Plummer et al., 2015). As expected, mCherry 
fluorescence was restricted to the soma and dendrites of the LC complex (Figure 3D, Figure 
S4). All remaining noradrenergic neurons, expressing only DbhFlpo, were labeled with eGFP 
(Figure S4).
Unexpectedly, we observed faint mCherry fluorescence in cerebellar Purkinje cells that have 
expressed En1cre but not DbhFlpo (Figure S5A). The absence of ectopic eGFP expression 
suggested that the ectopic mCherry results from mRNA splicing that occurs after Cre-
mediated recombination of the FLEx switch, rather than failure of the FRT-flanked stop 
cassette. To test this hypothesis, we performed RT-PCR analysis of cerebellum RNA and 
identified mRNA from RC::FL-hM3Dq in cells that have recombined the FLEx switch 
(Figure S5B). Due to a cryptic splice acceptor within the hM3Dq cDNA, this mRNA 
encodes mCherry but not the full hM3Dq-mCherry fusion. These experiments confirm that 
our alleles faithfully express hM3Dq-mCherry in the defined recombinase expression 
domains, demonstrating they can deliver hM3Dq to a variety of cell types limited only by 
the availability of Flp and Cre driver lines.
 Selective hM3Dq-mediated activation of noradrenergic neurons in vitro
To evaluate whether the level of hM3Dq expressed from RC::FL-hM3Dq is sufficient to alter 
cellular activity, we carried out whole-cell patch clamp recordings of noradrenergic neurons 
in the LC complex that express either hM3Dq-mCherry (En1cre; DbhFlpo; RC::FL-hM3Dq 
triple heterozygotes) or eGFP (DbhFlpo; RC::FL-hM3Dq controls) (Figure 4A). 
Fluorescence in the LC complex was readily detected in acute slice preparations (Figure 
4B). To evaluate whether CNO would depolarize hM3Dq-expressing neurons, we recorded 
in the presence of the Na+ channel blocker TTX (500 nM) or TTX plus the L-type Ca++ 
channel blocker nimodipine (1 μm) to eliminate network effects and oscillations. Average 
resting membrane potential was −56.0±11.0 mV, consistent with prior observations of locus 
coeruleus neurons (Williams et al., 1984; de Oliveira et al., 2010). Bath application of 10 μM 
CNO depolarized hM3Dq-mCherry+ LC complex neurons recorded in TTX (4.04±0.91 mV, 
n=5 neurons) or TTX+Nimodipine (1.60±0.27 mV, n=4 neurons). The depolarization 
measured under the two recording conditions was not statistically different (P=0.20), and 
therefore data were combined, yielding an average depolarization of 2.95±0.48 mV (Figure 
4C). In contrast, CNO had no effect on membrane potential of eGFP+ control neurons 
(Figure 4B-C). Depolarization by 50 μM NMDA, however, confirmed that these cells were 
healthy and responsive (Figure 4B). In the absence of CNO, hM3Dq-mCherry+ and eGFP+ 
neurons exhibited similar baseline membrane potential, capacitance, and membrane and 
input resistance (Figure 4C and data not shown), suggesting that mere expression of 
hM3Dq-mCherry does not impact membrane properties. To test whether expression of 
hM3Dq is sufficient to evoke neuronal firing, we next performed cell-attached recordings in 
the absence of TTX and nimodipine. Bath application of CNO (10 μM) increased the firing 
rate of hM3Dq-mCherry+ LC neurons by an average of 75.6±30.0% above baseline activity 
(0.91±0.08 Hz; n=6 cells; p<0.001; Figure 4D-E). To confirm that the ectopically labeled 
Purkinje cells do not express functional hM3Dq-mCherry fusion protein, we also performed 
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whole-cell recordings of these cells. Consistent with our identification of a nonfunctional 
mRNA, membrane potential of mCherry+ Purkinje cells was not altered by 10 μM CNO 
(Figure S5C). Taken together, these results demonstrate that the level of hM3Dq-mCherry 
expressed from RC::FL-hM3Dq permits chemogenetic activation of an intersectional 
subpopulation defined by expression of Cre and Flp.
 In vivo activation of the LC complex induces anxiety-like behavior and suppresses 
locomotion
We assessed the in vivo utility of our dual recombinase-responsive allele by testing whether 
expression of hM3Dq can alter anxiety-like behavior. Optogenetic stimulation of LC 
neurons at high, tonic frequency (5 Hz) prior to testing evokes anxiety-like behavior and 
suppresses locomotion (McCall et al., 2015). To test whether hM3Dq would evoke similar 
responses, we treated mice with CNO (1 mg/kg or 5 mg/kg, IP) or vehicle before testing in 
three assays: the elevated plus maze (EPM), light dark box (LDB), and open field test 
(OFT). In all three assays, CNO dose-dependently evoked anxiety-like responses and 
concomitantly suppressed locomotion of mice expressing hM3Dq-mCherry in the LC 
complex (Figure 5; Table S1). CNO at 5 mg/kg significantly induced anxiety-like behavior 
by reducing exploration within the aversive areas of the tests, including open arms of the 
EPM (Figure 5A), light compartment of the LDB (Figure 5B), and center zone of the OFT 
(Figure 5C and Figure S6) compared to vehicle. Both doses of CNO also suppressed 
locomotion, as shown by reduced closed arm entries in the EPM and distance ambulated in 
LDB and OFT compared to vehicle (Figure 5). CNO had no effect on behavioral 
performance of all littermate controls (Figure S7). In addition, mice expressing hM3Dq and 
all littermate controls were indistinguishable when treated with vehicle (Figure S7). 
Collectively, these data demonstrate that RC::FL-hM3Dq faithfullyexpresses hM3Dq at 
levels that permit sensitive control of an intersectionally targeted neuronal subpopulation 
and recapitulates behavioral phenotypes evoked by optogenetic stimulation.
 Dose-dependent activation of hM3Dq drives gamma oscillations in hippocampal neurons 
in vivo
Next, we assessed the efficacy of our single recombinase-responsive allele by testing 
whether hM3Dq can activate a dispersed neuronal population. In the original description of a 
tetracycline-controlled hM3Dq transgene, hippocampal gamma power was progressively 
evoked in Camk2a+ neurons following escalating doses of CNO (Alexander et al., 2009). To 
determine whether our Cre-responsive allele would evoke similar neural activity, we used 
the Camk2a-cre transgene (Tsien et al., 1996) to drive hM3Dq-mCherry expression (Figure 
6A). We recorded local field potentials in CA3 of the hippocampus of mice expressing 
hM3Dq-mCherry in Camk2a+ neurons (Camk2a-cre; RC::L-hM3Dq) and littermate 
controls. Consistent with the original study, we found that CNO dose-dependently increased 
hippocampal gamma power (50-80 Hz) in mice expressing hM3Dq-mCherry (Figure 6B-C). 
Doses of CNO as low as 1 mg/kg increased peak gamma power compared to vehicle. The 
10-mg/kg dose significantly increased gamma power 20 minutes following CNO injection, 
and gamma returned to baseline levels an hour thereafter (Figure 6C). In all littermate 
controls, CNO had no effect on peak gamma power (Figure 6C). These results confirm that 
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RC::L-hM3Dq can be used to efficiently and precisely control the activity of neuronal 
populations at levels measurable by in vivo electrophysiology.
 In vivo activation of hM3Dq expressed in glia elicits hypothermia
We further assessed the broad utility of RC::L-hM3Dq by targeting a dispersed population 
of non-neuronal cells. Activation of hM3Dq expressed in glia by a GFAP-hM3Dq transgene 
has previously been shown to induce hypothermia (Agulhon et al., 2013). To determine 
whether RC::L-hM3Dq can recapitulate this effect, we used the tamoxifen-inducible GFAP-
creERT2 transgene (Casper et al., 2007) to drive hM3Dq-mCherry expression in glia (Figure 
7A). Hypothermia was observed in mice expressing hM3Dq-mCherry in Gfap+ glia starting 
at 40 minutes after injection of CNO (5 mg/kg) and persisted until the test was stopped at 90 
minutes due to dangerously low body temperature (Figure 7B). In contrast, CNO did not 
alter body temperature in littermate controls (Figure 7C). Furthermore, we observed no 
effect of vehicle on body temperature (Figure 7B-C). Collectively, these data demonstrate 
that RC::L-hM3Dq permits activation of dispersed non-neuronal populations at levels 
sufficient to evoke lasting physiological changes.
 DISCUSSION
The experiments described here demonstrate that our Flp/Cre- and Cre-responsive hM3Dq 
alleles are valuable additions to the DREADD toolkit. The combination of CAG promoter 
and fusion protein for somatodendritic targeting of hM3Dq drives robust expression that is 
readily detected in live and fixed tissue across development. As demonstrated by our 
experiments, this level of expression is sufficient to non-invasively and dose-dependently 
manipulate cellular activity in diverse cell types, producing behavioral and physiological 
changes without undesired phenotypes associated with hM3Dq overexpression. A primary 
strength of DREADD technology is the ability to manipulate cellular activity in freely 
moving animals, but this advantage is compromised by strategies that require invasive 
delivery of the DREADD. For instance, viral injection of deep brain structures can result in 
significant damage to overlying parenchyma and even death of experimental animals. In 
contrast, our recombinase responsive hM3Dq alleles offer a truly non-invasive means to 
activate genetically defined cells.
These alleles offer several important advantages not shared by published hM3Dq alleles. 
RC::FL-hM3Dq offers intersectional genetic control of hM3Dq expression, thus providing 
increased spatial resolution by precise targeting of hM3Dq to cell populations defined by a 
shared history of Cre and Flp recombinase expression. Unlike existing Cre-responsive 
hM3Dq knock-in alleles (Teissier et al., 2015; Jackson Laboratory Stock #026220, 
unpublished reagent from U. Hochgeschwender and B. Roth), RC::FL-hM3Dq and RC::L-
hM3Dq utilize a FLEx switch for efficient control of expression, an mCherry fusion for 
endogenous fluorescent labeling, and a 2ACT88 epitope for somatodendritic targeting. 
These features ensure reliable expression of hM3Dq at levels that effectively permit both in 
vivo visualization and activation of genetically defined cells.
Our characterization of RC::FL-hM3Dq and RC::L-hM3Dq demonstrated that 
somatodendritic expression of hM3Dq can be obtained in virtually any cell population 
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across tissues and developmental stages. We observed the expected expression of mCherry 
and eGFP, confirming that the FRT-flanked stop cassette and Cre-dependent FLEx switch 
provide tight recombinase-responsive control of hM3Dq expression. Unexpectedly, we 
observed ectopic mCherry fluorescence in Cre+, Flp− cerebellar Purkinje cells of En1cre; 
DbhFlpo; RC::FL-hM3Dq mice. However, our RT-PCR and in vitro electrophysiology 
experiments unequivocally demonstrated that functional hM3Dq-mCherry is limited to the 
intersectional population of noradrenergic neurons that share a history of both Flp and Cre 
expression. Restriction of ectopic mCherry to a single cell type within the broad En1cre 
expression domain suggests that any ectopic fluorescence in other intersectional crosses will 
be similarly limited and will not interfere with experiments.
We validated the in vivo functional capabilities of RC::FL-hM3Dq and RC::L-hM3Dq in 
three distinct cell types. Activation of hM3Dq expressed bilaterally in the LC complex dose-
dependently evoked anxiety-like behavior and suppressed locomotion, consistent with 
results following unilateral high tonic (5 Hz) optogenetic stimulation of the locus coeruleus 
(McCall et al., 2015). The subtle changes in anxiety and locomotion we observed were not 
obscured by the complete behavioral arrest that was reported following prolonged, high 
frequency optogenetic stimulation (>5 Hz) (Carter et al., 2010). Using RC::L-hM3Dq, we 
dose-dependently induced gamma oscillations in Camk2a-cre+ hippocampal neurons, 
consistent with results using the tetracycline-controlled TRE-hM3Dq transgene (Alexander 
et al., 2009). Notably, the changes in neural activity we observed were not accompanied by 
limbic seizures, an extreme phenotype observed using the TRE-hM3Dq transgene. 
Additionally, activation of hM3Dq in GFAP+ glia dose-dependently evoked long-lasting 
changes in body temperature, consistent with prior results (Agulhon et al., 2013).
While all of these phenotypic changes emerged on the timescale of minutes following 
activation of hM3Dq, their onset differed across experiments. Given that systemically 
administered CNO is rapidly observed in the brain (Bender et al. 1994), this varied onset of 
phenotype is likely dependent on the targeted cell type, phenotypic endpoint, and CNO dose 
employed. Our findings further suggest that levels of hM3Dq expression also influence the 
onset of phenotype. For example, the hypothermia we observed was slower to emerge than 
previously described using a GFAP-hM3Dq transgene (Agulhon et al 2013). This result, 
together with the absence of extreme phenotypes like seizures or behavioral arrest in the 
other crosses, is likely due to lower levels of hM3Dq expression from our single-copy 
knock-in allele compared to transgenic or viral delivery. Taken together, these findings 
indicate that our hM3Dq alleles modulate cellular activity to produce physiologically 
relevant changes in behavior without untoward effects that impede or confound 
interpretation.
In summary, RC::FL-hM3Dq and RC::L-hM3Dq take full advantage of the power of 
DREADD technology to non-invasively manipulate cellular activity. Our characterization of 
these alleles demonstrates their capacity to target genetically defined cell populations, 
regardless of anatomical location or distribution. In addition, the ability to express hM3Dq at 
any time-point offers the opportunity to uncover the functional consequences of cellular 
activation throughout development. Together, these capabilities render the hM3Dq alleles 
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broadly useful for controlling the activity of diverse cell types to uncover their function and 
dysfunction.
 EXPERIMENTAL PROCEDURES
Procedures related to the use of mice were conducted according to NIH guidelines and the 
National Research Council Guide for the Care and Use of Laboratory Animals (Publication 
No. 85-23, revised 2013). The Institutional Animal Care and Use Committee (IACUC) of 
the National Institute of Environmental Health Science and University of North Carolina 
approved all experiments. Detailed methods are provided in the Supplemental Experimental 
Procedures.
 Generation of Mouse Lines
To generate our targeting vector for homologous recombination in embryonic stem cells, we 
first modified a Cre-dependent FLEx switch (Atasoy et al., 2008; Schnutgen et al., 2003) by 
insertion of an eGFP cDNA and rabbit β-globin polyadenylation cassette between the 5’ 
lox2272 and loxP sites. We amplified FRT-flanked and rox-flanked His3-SV40 
transcriptional stop cassettes, using as the PCR template a pBS302 plasmid (Sauer, 1993) 
modified to remove the internal MfeI site. The stop cassettes and FLEx switch containing 
eGFP were then cloned into the Gt(ROSA)26Sor targeting vector pRC-RFLTG (Plummer et 
al., 2015) after digestion with MluI and FseI. The digested fragment of pRC-RFLTG 
provided a CAG promoter (Niwa et al., 1991), woodchuck hepatitis virus posttranscriptional 
regulatory element (WPRE) (Zufferey et al., 1999), bGH poly(A) cassette, the 5’ and 3’ 
homology to the Gt(ROSA)26Sor locus, and attB/attP-flanked Neo cassette. A cDNA 
encoding the hM3Dq-mCherry-2ACT88 fusion protein, which contains the final 264 coding 
nucleotides of the rat Htr2A gene (Xia et al., 2003), was generously provided by Bryan Roth 
(University of North Carolina). This cDNA was cloned into the center of the modified FLEx 
switch, in antisense orientation relative to the CAG promoter and eGFP cDNA, to produce 
the final targeting vector pRC-RFL-hM3Dq.
Linearized pRC-RFL-hM3Dq was electroporated into G4 embryonic stem cells (George et 
al., 2007) obtained from the Lunenfeld-Tanenbaum Research Institute (Toronto, Canada), 
and long range PCR and Southern blotting identified homologous recombinants. A 
recombinant clone was transiently transfected with pPGKPhiC31obpa (Raymond and 
Soriano, 2007) to remove the attb-attp-flanked Neo cassette, and two subclones were 
injected into B6(Cg)-Tyrc-2J/J blastocysts to produce chimeric mice. The RC::FL-hM3Dq 
strain was established by breeding chimeras with B6;129-Tg(CAG-dre)1Afst mice 
(Anastassiadis et al., 2009) to excise the rox-flanked stop cassette, and the RC::L-hM3Dq 
strain was established by crossing RC::FL-hM3Dq with B6.Cg-Tg(ACTFlpe)9205Dym/J 
mice (ACTB-Flpe) (Rodriguez et al., 2000) to excise the FRT-flanked stop cassette. Both 
strains were maintained by backcrossing to C57BL/6J mice.
 Experimental Crosses
To demonstrate ubiquitous expression of eGFP and hM3Dq-mCherry encoded by our 
DREADD alleles, we crossed RC::FL-hM3Dq mice with ACTB-Flpe followed by B6;FVB-
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Tg(ACTB-cre)2Mrt (ACTB-cre) (Lewandoski et al., 1997). Embryos were collected at 
embryonic day (E) 11.5, and adult organs were collected from 10-week old mice. RC:L-
hM3Dq mice were separately crossed with B6(C3)-Tg(GFAP-cre/ERT2)13Kdmc (Casper et 
al., 2007) and B6.Cg-Tg(Camk2a-cre)T29-1Stl (Tsien et al., 1996) mice. To generate En1cre; 
DbhFlpo; RC::FL-hM3Dq mice, RC::FL-hM3Dq mice were first crossed to B6;129-
Dbhtm1(Flpo)Pjen (DbhFlpo) heterozygotes (Robertson et al., 2013), and offspring were 
backcrossed to generate animals heterozygous for DbhFlpo and homozygous for RC::FL-
hM3Dq. The mice were subsequently crossed with B6.Cg-En1tm2(cre)Wrst (En1cre) 
heterozygotes (Kimmel et al., 2000) to generate En1cre; DbhFlpo; RC::FL-hM3Dq triple 
heterozygotes.
 Tissue Collection and Immunohistochemistry
Embryos were fixed overnight by immersion in 4% paraformaldehyde (PFA) in 0.01 M 
phosphate-buffered saline (PBS) at 4°C. Adult mice were anesthetized with sodium 
pentobarbital (0.1 mL of 50 mg/mL i.p.) and perfused transcardially with PBS followed by 
4% PFA in PBS. Brains were postfixed overnight by immersion in 4% PFA at 4°C, and then 
rinsed in PBS before transfer to 30% sucrose in PBS for 48 hours at 4°C. Tissue for 
immunohistochemistry was embedded in Tissue Freezing Medium (General Data Company, 
Cincinnati, OH) and sectioned at 40-μm on a Leica CM3050-S cryostat (Leica Biosystems, 
Buffalo Grove, IL). Free-floating sections were collected for immunolabeling using 
antibodies described in Supplemental Experimental Procedures. After staining, sections 
were mounted on microscope slides and coverslips were attached with Vectashield or 
Vectashield plus DAPI (Vector Laboratories, Burlingame, CA) before imaging.
 Digital Image Processing
Images of native fluorescence in whole embryos and adult brains were collected on a Zeiss 
SteREO Lumar.V12 stereomicroscope (Carl Zeiss Microscopy, Thornwood, NY). Images of 
the LC complex from acute slices were acquired using a Zeiss Axio Examiner microscope 
and camera (Axiocam 503) equipped with Zen 2012 Blue Software (Carl Zeiss). The images 
of acute slices were processed with ImageJ software (US National Institutes of Health) by 
merging color channels, adjusting brightness and contrast, and applying a smoothing filter. 
Images of immunofluorescent-labeled sections were collected on a Zeiss LSM 710, 780, or 
880 inverted confocal microscope. Zen 2012 Black Software (Carl Zeiss) was used to 
convert z-stacks to maximum intensity projections. Images were modified only by brightness 
and contrast adjustments to optimize the full dynamic range of the fluorescence signal. 
Anatomical location was confirmed by reference to a mouse brain atlas (Paxinos and Franks, 
2013).
 Slice Electrophysiology
Following anesthesia of En1cre; DbhFlpo; RC::FL-hM3Dq and littermate mice, coronal 
hindbrain slices (250 μm) were cut in ice-cold cutting solution and incubated at 28-30°C in 
oxygenated aCSF for at least 30 min. All solutions are listed in the Supplemental 
Experimental Procedures. Slices were transferred to a recording chamber and perfused with 
aCSF (32°C) at 2 mL/min. Patch electrodes (1-5 MΩ) were pulled from borosilicate glass. 
To determine whether CNO (10 μM) would alter membrane potential, whole-cell current-
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clamp recordings were made from eGFP+ and hM3Dq-mCherry+ LC neurons in the 
presence of TTX (500 nM) and nimodipine (1 μM). To confirm the absence of functional 
hM3Dq, recordings were similarly made from mCherry+ cerebellar Purkinje cells. Cell-
attached voltage-clamp recordings were also made from hM3Dq-mCherry+ LC neurons to 
quantify the increase in firing events elicited by CNO (10 μM). Data were collected at 10 
kHz using an EPC 800 amplifier (HEKA) and DigiData 132x digitizer (Molecular Devices). 
Analyses were performed in ClampFit 10.4 on traces that were filtered at 3 Hz (voltage 
traces) or 1 Hz (current traces).
 Anxiety-like Behavior
En1cre; DbhFlpo; RC::FL-hM3Dq and littermate mice were randomly assigned to receive two 
i.p. injections of vehicle or CNO (1 or 5 mg/kg). Mice received the first injection 
immediately before the open field test, and the second injection was 2-3 days later, 
approximately 15 min before the light dark box. Mice were tested in the elevated plus maze 
directly after the light dark box. Details of the tests are described below and in Supplemental 
Experimental Procedures.
 Open Field Test—Mice were placed in an open arena (27 × 27 × 20 cm, Med 
Associates) that was not illuminated (0 lux). Exploration in the center (14.3 × 14.3 cm) and 
remaining periphery of the arena was measured for 90 min.
 Light Dark Box—Mice were allowed to freely explore an arena (27 × 27 × 20 cm, Med 
Associates) that was divided into two equal compartments. Exploration in the dark (0 lux) 
and light compartment (~950 lux) of the arena was measured for 10 min.
 Elevated Plus Maze—Mice were placed on a ‘+’ shaped maze that was brightly 
illuminated (300 lux) and elevated 20”. Exploration in the open (11 × 2 inch) and closed 
arms of the maze (11 × 2 × 5”) was measured for 5 min, as previously described (Sciolino et 
al., 2015).
 In Vivo Electrophysiology
A 10-channel array (44-μm polyimide-coated steel wires, Sandvic), soldered to circuit board 
(San Francisco Circuits) and connector (Omnetics), was implanted into the hippocampus of 
anesthetized Camk2a-cre; RC::L-hM3Dq and littermate control mice using the following 
stereotaxic coordinates (mm): −2.06 anteroposterior, 2.1 mediolateral, 2.1 dorsoventral from 
bregma (Paxinos and Franks, 2013). Local field potentials were recorded using a 32-channel 
wireless headstage (Triangle BioSystems International) and Cerebus acquisition system 
(Blackrock Microsystems). During recordings, mice were placed in a plexiglass chamber 
(20” × 20”) and given i.p. injection of vehicle or the following escalating doses of CNO: 
0.03, 0.1, 0.3, 0.5, 1, 5 and 10 mg/kg, as previously described (Alexander et al. 2009). All 
mice received each dose of CNO with 2-3 days between treatments. Analyses were 
performed in Matlab R2014a (MathWorks Inc.) using Chronux software on traces that were 
band-pass filtered (0.3-500 Hz) and stored at 1 kHz. Details are provided in the 
Supplemental Experimental Procedures.
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 Tamoxifen Dosing
Tamoxifen (T5648, Sigma Aldrich, St. Louis, MO) was dissolved in 10:1 corn oil:ethanol at 
a concentration of 20 mg/ml (w./v.). To induce Cre-mediated recombination, GFAP-
creERT2; RC::L-hM3Dq double heterozygous mice and littermate controls received five 
daily doses of tamoxifen (100 mg/kg i.p., 0.05 ml/10 g body weight) during postnatal week 
6 to 12.
 Body Temperature
Tamoxifen-treated GFAP-creErt2; RC::L-hM3Dq and littermate mice were briefly restrained 
for baseline measurement of body temperature using a rectal probe. Following i.p. injection 
of vehicle or CNO (1 or 5 mg/kg), body temperature was measured in 10 min intervals for 
90 min. A heating pad was provided to hypothermic mice after testing. All mice were tested 
twice with at least 5 days of recovery between the tests.
 Data Analysis and Statistics
All data are reported as mean ± SEM. Datasets met normality (Shapiro-Wilk test) and equal 
variance (Levine test) assumptions. Differences between groups were determined using t-
tests or ANOVA. Bonferroni post-hoc tests were performed when necessary to correct for 
multiple comparisons. Significance for all analyses was set to p<0.05. Analyses were 
performed using GraphPad Prism 6.0, Matlab R2014a, and IBM SPSS 21.0. Details for the 
analyses are described in the Supplemental Experimental Procedures.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• Recombinase-responsive mice express hM3Dq DREADD for induction of 
cellular activity
• Targeting of hM3Dq to cell body and dendrites to increase effective 
expression levels
• mCherry fusion permits visualization of hM3Dq+ cells in vivo
• Dose-dependent activation of hM3Dq drives behavioral and physiological 
changes
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Figure 1. Recombinase-responsive alleles for somatodendritic targeting of hM3Dq
(A) Schematic diagrams of RC::FL-hM3Dq and RC::L-hM3Dq shown in relation to the 
Gt(ROSA)26Sor locus. In both alleles, a CAG promoter drives gene expression. RC::FL-
hM3Dq expresses eGFP after Flp-mediated excision of the FRT-flanked His3-SV40 stop 
cassette (STOP). hM3Dq-mCherry fusion protein is expressed after excision of the stop 
cassette and recombination of lox2272 and loxP sites constituting the Cre-dependent FLEx 
switch. RC::L-hM3Dq expresses eGFP ubiquitously and hM3Dq-mCherry after Cre-
mediated recombination of the FLEx switch. 2ACT88, c-terminal fragment of HTR2A; 
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WPRE, woodchuck hepatitis virus posttranscriptional regulatory element; poly(A), bovine 
growth hormone polyadenylation signal. (B) Native eGFP and mCherry fluorescence in 
E11.5 embryos. Top: Absence of fluorescence in RC::FL-hM3Dq heterozygote confirms that 
the FRT-flanked stop cassette blocks expression in the absence of Flp activity. Middle: 
Ubiquitous eGFP fluorescence, but no mCherry, in RC::L-hM3Dq heterozygote confirms 
that the FLEx switch blocks hM3Dq expression in the absence of Cre activity. Bottom: 
Ubiquitous mCherry fluorescence observed after crossing RC:: L-hM3Dq with a 
ubiquitously expressed ACTB-cre transgene (Lewandoski et al., 2007) confirms 
recombination of the Cre-dependent FLEx switch. Scale bar: 2 mm.
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Figure 2. Widespread expression of hM3Dq-mCherry after recombination of RC::FL-hM3Dq by 
ubiquitous Flp and Cre driver alleles
(A) Sagittal section of ACTB-cre; ACTB-Flpe; RC::FL-hM3Dq brain immunolabeled for 
mCherry (red) and the neuronal marker NeuN (white). Boxes show location of magnified 
images (below). Following ubiquitous recombinase expression, mCherry is observed 
throughout the brain. Fluorescence is attenuated in regions with a high proportion of axons 
(e.g. corpus callosum), consistent with somatodendritic targeting of hM3Dq-mCherry. Scale 
bar: 2000 μm (full sagittal section) or 244 μm (magnified images). (B) Sections of ACTB-
cre; ACTB-Flpe; RC::FL-hM3Dq brain immunolabeled for mCherry (red) and markers of 
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neuronal and glial subtypes (white). hM3Dq-mcherry is observed in midbrain dopaminergic 
neurons labeled for tyrosine hydroxylase (TH), cortical interneurons labeled for 
parvalbumin, and astrocytes labeled for glial fibrillary acidic protein (GFAP). Scale bar: 20 
μm.
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Figure 3. Somatodendritic targeting of hM3Dq-mCherry in neurons and glia
(A) Hippocampal CA3 neurons in a Camk2a-cre; RC::L-hM3Dq brain immunolabeled for 
mCherry (red) and nuclear NeuN (white). (B) Cortical neurons from a Camk2a-cre; RC::L-
hM3Dq brain immunolabeled for mCherry (red) and NeuN (white). (C) Cortical astrocyte 
from a GFAP-CreERT2; RC::L-hM3Dq brain immunolabeled for mCherry (red) and GFAP 
(white). (D) Noradrenergic neuron from an En1Cre; DbhFlpo; RC::FL-hM3Dq brain 
immunolabeled for mCherry (red) and tyrosine hydroxylase (white). Images taken from 
coronal sections. Scale bar: 40 μm (A,B) or 20 μm (C,D).
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Figure 4. Intersectional genetic strategy for selective, noninvasive expression of hM3Dq and 
activation of the LC complex
(A) Schematic diagram of RC::FL-hM3Dq, sagittal diagram of noradrenergic nuclei in the 
hindbrain, and coronal sections through the LC complex immunolabeled for tyrosine 
hydroxylase (white), eGFP (green), and mCherry (red). Top: In the absence of recombinase 
expression, noradrenergic neurons are not labeled by eGFP or mCherry. Middle: 
Recombination of RC::FL-hM3Dq by DbhFlpo results in eGFP expression in noradrenergic 
neurons. Bottom: Recombination of RC::FL-hM3Dq by En1cre and DbhFlpo results in 
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hM3Dq-mCherry expression in noradrenergic neurons of the LC complex. (B) Top: Acute 
hindbrain slices show endogenous expression of eGFP (DbhFlpo; RC::FL-hM3Dq) and 
hM3Dq-mCherry (En1cre; DbhFlpo; RC::FL-hM3Dq) in LC complex neurons patched using 
Alexa350-filled electrodes (blue). Scale bar: 20 μm. Bottom: Representative traces from 
whole-cell recordings taken from LC neurons with TTX (500 nM) and nimodipine (1μM) 
present. Bath application of CNO (10 μM) depolarizes hM3Dq-mCherry+ neurons from 
resting membrane potential (dashed line). CNO has no effect on membrane potential of 
eGFP+ neurons, but NMDA (50 μM) does induce depolarization. (C) Left: Average mV 
depolarization by CNO (10 μM) from baseline recorded in hM3Dq-mCherry+ (En1cre; 
DbhFlpo; RC::FL-hM3Dq, n=9 cells from 7 mice) and eGFP+ (DbhFlpo; RC::FL-hM3Dq, 
n=9 cells from 4 mice) LC complex neurons. **p<0.01 (t-test). Right: Population data show 
the effect of CNO (10 μM) on membrane potential in individual mCherry+ and eGFP+ LC 
neurons. ***p<0.001 (Bonferroni). (D) Representative trace of cell-attached recordings from 
an hM3Dq-mCherry+ neuron. Insets of trace show individual firing events in epochs 
occurring before (left), during (middle), and after (right) superperfusion of CNO. Dashed 
line indicates the average holding current. (E) Left: Bath application of CNO (10 μM) 
increases firing rate of hM3Dq-mCherry+ neurons (En1cre; DbhFlpo; RC::FL-hM3Dq, n=6 
cells from 3 mice). Right: Population data show the effect of CNO (10 μM) on firing rate in 
individual hM3Dq-mCherry+ LC neurons. ***p<0.001 (t-test).
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Figure 5. CNO is sufficient to drive anxiety-like behavior and suppress locomotion in mice 
expressing hM3Dq-mCherry in the LC complex
(A-C) Behavioral data from elevated plus maze (EPM), light-dark box (LDB), and open 
field test (OFT). Data are Mean ± SEM for mice given vehicle (n=18-21), CNO 1-mg/kg 
(n=16-20), and CNO 5-mg/kg (n=13-15) treated En1cre; DbhFlpo; RC::FL-hM3Dq mice. 
***p<0.001, **p<0.01, *p<0.05 vs. Vehicle (Bonferroni). ++p<0.01 vs. Vehicle and 1-
mg/kg CNO (Bonferroni). Exact p values list trends for a statistical difference versus 
vehicle.
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Figure 6. Dose-dependent induction of hippocampal gamma oscillations by CNO in mice 
expressing hM3Dq-mCherry in Camk2a+ neurons
(A) Schematic diagram shows Cre-mediated recombination of the FLEx switch permitting 
hM3Dq-mCherry expression. Coronal section through the hippocampus of a Camk2a-cre; 
RC::L-hM3Dq double heterozygote, immunolabeled for mCherry (red) and NeuN (white). 
Scale bar: 500 μm. (B) Spectrograms show frequency composition of local field potentials 
(LFP) recorded from Camk2a-cre; RC::L-hM3Dq mice before, during and after 
administration of vehicle or CNO at 1 or 10 mg/kg i.p. (C) LFP data were divided into five-
minute time bins, and power spectral densities were computed. Pre-CNO power was the 
average gamma power (50-80 Hz) across 0-25 min. The 25-30 min bin was not included for 
analysis because mice were handled and injected. Gamma power post-CNO injection was 
normalized to pre-CNO power. Peak gamma power was averaged across 65-80 min bins 
(i.e., 35-50 min post-CNO) and normalized to pre-CNO. Mice were administered all doses 
listed. Top: Time course of gamma power for vehicle- and CNO-treated Camk2a-cre; RC::L-
hM3Dq double heterozygotes. The yellow window indicates the time period during which 
CNO increased gamma power. N=4 mice. Bottom: Peak gamma power following CNO 
injection for Camk2a-cre; RC::L-hM3Dq and littermate control mice demonstrates dose 
dependence. ***p<0.001, *p<0.05 vs. Vehicle (Bonferroni). +p<0.05 vs. both CNO 1 mg/kg 
and Vehicle (Bonferroni).
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Figure 7. Activation of hM3Dq-mCherry in glia is sufficient to elicit hypothermia
(A) Schematic diagram shows Cre-mediated recombination of the FLEx switch permitting 
hM3Dq-mCherry expression in glia of mice treated with tamoxifen. (B) Decreased body 
temperature in GFAP-creErt2; RC::L-hM3Dq double heterozygotes following CNO. Data 
are Mean ± SEM for mice given vehicle (n=5) or CNO 1 and 5 mg/kg (n=6). *p<0.05 vs. 
vehicle (Bonferroni). +p<0.05 vs. vehicle and CNO 1 mg/kg (Bonferroni). (C) CNO has no 
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effect on the body temperature of littermate controls. +p<0.05 vs. vehicle and CNO 1 mg/kg 
(Bonferroni).
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